Chinese herbal medicine reduces mortality in patients with severe and critical Coronavirus disease 2019: a retrospective
- PDF / 181,902 Bytes
- 8 Pages / 595.276 x 785.197 pts Page_size
- 113 Downloads / 215 Views
RESEARCH ARTICLE
Chinese herbal medicine reduces mortality in patients with severe and critical coronavirus disease 2019: a retrospective cohort study Guohua Chen1,*, Wen Su1,*, Jiayao Yang1,*, Dan Luo1,*, Ping Xia1, Wen Jia1, Xiuyang Li2, Chuan Wang1, Suping Lang3, Qingbin Meng1, Ying Zhang4, Yuhe Ke1, An Fan3, Shuo Yang1, Yujiao Zheng2, Xuepeng Fan1, Jie Qiao5,
Fengmei Lian (✉)2, Li Wei (✉)1, Xiaolin Tong (✉)2 1
Wuhan No.1 Hospital (Wuhan Integrated TCM & Western Medicine Hospital), Wuhan 430022, China; 2Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China; 3GCP ClinPlus Co., Ltd., Beijing 100160, China; 4Beijing University of Chinese Medicine, Beijing 100029, China; 5Hubei University of Traditional Chinese Medicine, Wuhan 430060, China
© Higher Education Press 2020
Abstract This study aimed to evaluate the efficacy of Chinese herbal medicine (CHM) in patients with severe/ critical coronavirus disease 2019 (COVID-19). In this retrospective study, data were collected from 662 patients with severe/critical COVID-19 who were admitted to a designated hospital to treat patients with severe COVID-19 in Wuhan before March 20, 2020. All patients were divided into an exposed group (CHM users) and a control group (non-users). After propensity score matching in a 1:1 ratio, 156 CHM users were matched by propensity score to 156 non-users. No significant differences in seven baseline clinical variables were found between the two groups of patients. All-cause mortality was reported in 13 CHM users who died and 36 non-users who died. After multivariate adjustment, the mortality risk of CHM users was reduced by 82.2% (odds ratio 0.178, 95% CI 0.076– 0.418; P < 0.001) compared with the non-users. Secondly, age (odds ratio 1.053, 95% CI 1.023–1.084; P < 0.001) and the proportion of severe/critical patients (odds ratio 0.063, 95% CI 0.028–0.143; P < 0.001) were the risk factors of mortality. These results show that the use of CHM may reduce the mortality of patients with severe/ critical COVID-19. Keywords
COVID-19; CHM; mortality; a retrospective cohort study
Introduction In December 2019, a breakout of coronavirus disease 2019 (COVID-19) was reported. The World Health Organization (WHO) has declared COVID-19 as a global pandemic [1]. At present, the number of death cases from COVID-19 is increasing rapidly, and its mortality rate is significantly higher than that of influenza [2]. By March 29, 2020, the total number of confirmed cases worldwide was 634 835, and the number of deaths was as high as 29 891 [3]. No vaccine or antiviral medicine has confirmed clinical effect
Received April 14, 2020; accepted July 8, 2020 Correspondence: Fengmei Lian, [email protected]; Li Wei, [email protected]; Xiaolin Tong, [email protected] *
These authors contributed equally to this work.
to prevent or treat COVID-19 currently, which has brought great difficulties to the prevention and control of the epidemic [4]. A recent clinical study has reported that the antiviral drugs lopinavir and ritonavir have no c
Data Loading...
